Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
NCT01608815Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2012
- Primary completion
- Sep 2012
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of salmonella typhi capsular polysaccharide vaccine in typhoid fever, sponsored by Sanofi. Primary endpoint: Percentage of subjects with at least a 4-fold increase of their Vi antibody titer at Day 28. Started May 2012; status: completed.
02
Drugs
salmonella typhi capsular polysaccharide vaccine
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT01608815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01608815.